Urethral Squamous Cell Carcinoma
NCI Definition: A well differentiated, moderately differentiated, or poorly differentiated squamous cell carcinoma that arises from the male or female urethra. 
Urethral squamous cell carcinomas most frequently harbor alterations in PIK3CA, TP53, PIK3C2G, YES1, and SOCS1 .
PIK3CA Mutation, PIK3CA E542K, PIK3CA Codon 542 Missense, TP53 c.217-c.1178 Missense, and TP53 Mutation are the most common alterations in urethral squamous cell carcinoma .
There are 2 clinical trials for urethral squamous cell carcinoma, of which 1 is open and 1 is completed or closed. Of the trials that contain urethral squamous cell carcinoma as an inclusion criterion, 2 are phase 2 (1 open).
Durvalumab, ipilimumab, and nivolumab are the most common interventions in urethral squamous cell carcinoma clinical trials.
Significant Genes in Urethral Squamous Cell Carcinoma
CD274 is an inclusion eligibility criterion in 1 clinical trial for urethral squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CD274 status and urethral squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.